Surgery following neoadjuvant chemotherapy for non-small-cell lung cancer patients with unexpected persistent pathological N2 disease

Molecular and Clinical Oncology
Xue-Fei HuK E Fei

Abstract

Patients with mediastinal lymph node (LN) downstaging following neoadjuvant chemotherapy exhibit improved outcomes compared with patients with persistent N2 disease. The aim of this study was to compare clinicopathological characteristics and survival between patients with unexpected and expected persistent N2 disease following surgery for non-small-cell lung cancer (NSCLC). This retrospective analysis included 348 patients with NSCLC who underwent surgery following chemotherapy at the Shanghai Pulmonary Hospital, Tongji University School of Medicine, between 1995 and 2012. According to the results of the imaging examinations and postoperative pathology, the patients were divided into three groups, namely groups I (nodal downstaging, pN0-1), II (expected persistent N2 disease) and III (unexpected persistent N2 disease). The rates of overall survival (OS) and disease-free survival (DFS) were estimated by the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify the independent risk factors for OS and DFS. The mortality rate was 1.1% during the postoperative period. Perioperative complications occurred in 45 patients (12.9%). The 5-year OS rate was 32.2, 6.3 and 25.9% in groups I, II and III, respec...Continue Reading

References

Jun 1, 1992·The Annals of Thoracic Surgery·H I PassJ Minna
Oct 1, 1987·The Surgical Clinics of North America·N Martini, B J Flehinger
Jan 1, 1981·Cancer·A B MillerA Winkler
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F AndreT Le Chevalier
Feb 13, 2003·The Journal of Thoracic and Cardiovascular Surgery·Kanji NagaiUNKNOWN Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel C BetticherHans-Beat Ris
Nov 3, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N LorentUNKNOWN Leuven Lung Cancer Group
Apr 28, 2005·The Annals of Thoracic Surgery·Jeffrey L PortNasser K Altorki
Mar 22, 2007·Journal of the National Cancer Institute·Jan P van MeerbeeckUNKNOWN European Organisation for Research and Treatment of Cancer-Lung Cancer Group
Sep 1, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Patti A GroomeUNKNOWN Participating Institutions
Sep 1, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Peter GoldstrawUNKNOWN Participating Institutions
Oct 6, 2007·Chest·Gerard A SilvestriUNKNOWN American College of Chest Physicians
Nov 6, 2007·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Nael Al-SarrafVincent Young
Dec 18, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hong Kwan KimJhingook Kim
Apr 7, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Apar PataerUNKNOWN University of Texas M. D. Anderson Lung Cancer Collaborative Research Group

❮ Previous
Next ❯

Citations

Feb 6, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Ya-Fu ChengBing-Yen Wang
Aug 8, 2018·Interactive Cardiovascular and Thoracic Surgery·Serkan YazganTarik Yagci

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.